Grape King Bio Ltd. (1707) AI Stock Analysis

Grape King Bio Ltd.

(TWSE:1707)

Select Model

Rating:73Outperform

Price Target:TWD 90.00▲(14.36% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported most by the exceptionally strong balance sheet, solid profitability and cash generation, and attractive valuation. These strengths are tempered by weakening operating momentum and clearly bearish technical positioning, despite oversold indicators.

Positive Factors

Strong ProfitabilityConsistently high gross margins and healthy operating margins indicate that Grape King retains substantial economics after production costs. This provides resilience against moderate cost pressure, supports ongoing investment in functional products, and gives the business a durable base for profitability over the next several quarters.

Negative Factors

Revenue DeclineThe return to revenue contraction indicates that recent demand and sales momentum have weakened, limiting operating leverage and the company’s ability to grow earnings through expansion. If this persists, it could reduce investment capacity and make future profit growth increasingly dependent on cost control.

Grape King Bio Ltd. (1707) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 11.60B
Dividend Yield: 7.57%
Average Volume (3M): 387.04K
Price to Earnings (P/E): 11.0
Beta (1Y): 0.11
Revenue Growth: -5.38%
EPS Growth: -12.85%
Country: TW
Employees: 501
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Grape King Bio Ltd. Business Overview & Revenue Model

Company Description

Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market pr...

Grape King Bio Ltd. Financial Statement Overview

Summary

Strong overall financial quality, led by an exceptionally solid balance sheet and positive cash generation. Profitability remains healthy, but declining revenue, margins, net income, return on equity, and longer-term free cash flow reduce the score.

Income Statement

68Positive

Balance Sheet

94Very Positive

Cash Flow

76Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.12B	10.25B	11.16B	10.64B	10.39B	9.80B
Gross Profit	7.38B	7.70B	8.66B	8.54B	8.48B	7.86B
EBITDA	2.63B	2.69B	3.17B	3.12B	3.13B	2.83B
Net Income	1.15B	1.22B	1.45B	1.45B	2.17B	1.95B
Balance Sheet
Total Assets	15.00B	15.74B	15.32B	15.51B	15.05B	14.06B
Cash, Cash Equivalents and Short-Term Investments	3.70B	4.28B	4.43B	4.97B	4.79B	3.90B
Total Debt	186.69M	215.03M	160.91M	192.92M	157.75M	271.76M
Total Liabilities	3.40B	3.67B	3.53B	3.88B	3.91B	3.63B
Stockholders Equity	10.24B	10.34B	10.06B	9.98B	9.57B	8.99B
Cash Flow
Free Cash Flow	1.50B	1.73B	1.23B	1.92B	2.49B	2.26B
Operating Cash Flow	1.99B	2.18B	1.88B	2.52B	2.99B	2.54B
Investing Cash Flow	-724.19M	-580.08M	-662.11M	-654.73M	-330.31M	-462.34M
Financing Cash Flow	-1.62B	-1.77B	-1.72B	-1.71B	-1.63B	-1.37B

Grape King Bio Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1707 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1707	73Outperform	TWD 11.75B	11.04	―	7.57%	-5.38%	-12.85%
TW:8462	68Neutral	TWD 12.09B	14.08	―	4.84%	19.42%	56.90%
TW:8436	62Neutral	TWD 10.68B	9.60	―	6.52%	-3.82%	2.23%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1234	54Neutral	TWD 12.84B	19.48	―	5.16%	-7.77%	-27.50%
TW:6617	40Underperform	TWD 15.11B	-89.26	―	―	11.66%	-72.43%

* General Sector Average

Performance Comparison

TW:1707 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1707	Grape King Bio Ltd.	78.70	-43.39	-35.54%
TW:1234	Hey-Song Corp.	31.90	-3.64	-10.24%
TW:6617	Gongwin Biopharm Holdings Co., Ltd.	126.50	41.90	49.53%
TW:7780	Daiken Biomedical Co., Ltd.	15.10	-2.05	-11.97%
TW:8436	TCI Co., Ltd.	91.40	-24.30	-21.00%
TW:8462	Power Wind Health Industry Incorporated	146.50	-1.64	-1.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Grape King Bio Ltd. AI Stock Analysis